These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 11479150

  • 1. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens.
    Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, Wong RW, Au TC.
    Am J Kidney Dis; 2001 Aug; 38(2):256-64. PubMed ID: 11479150
    [Abstract] [Full Text] [Related]

  • 2. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, Wong RW, Lau CS.
    Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
    [Abstract] [Full Text] [Related]

  • 3. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RW, Au TC.
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [Abstract] [Full Text] [Related]

  • 4. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [Abstract] [Full Text] [Related]

  • 5. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
    Grootscholten C, Bajema IM, Florquin S, Steenbergen EJ, Peutz-Kootstra CJ, Goldschmeding R, Bijl M, Hagen EC, Van Houwelingen HC, Derksen RH, Berden JH, Dutch Working Party on Systemic Lupus Erythematosus.
    Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
    [Abstract] [Full Text] [Related]

  • 6. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis.
    Arends S, Grootscholten C, Derksen RH, Berger SP, de Sévaux RG, Voskuyl AE, Bijl M, Berden JH, Dutch Working Party on systemic lupus erythematosus.
    Ann Rheum Dis; 2012 Jun; 71(6):966-73. PubMed ID: 22128082
    [Abstract] [Full Text] [Related]

  • 7. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R, Stojanović R, Novicić-Sasić D, Dimitrijević J, Pavlović S, Stojković D, Palić-Obradović D, Stevanović G, Prodanović S.
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [Abstract] [Full Text] [Related]

  • 8. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.
    Yee CS, Gordon C, Dostal C, Petera P, Dadoniene J, Griffiths B, Rozman B, Isenberg DA, Sturfelt G, Nived O, Turney JH, Venalis A, Adu D, Smolen JS, Emery P.
    Ann Rheum Dis; 2004 May; 63(5):525-9. PubMed ID: 15082482
    [Abstract] [Full Text] [Related]

  • 9. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine.
    Mok CC, Ho CT, Chan KW, Lau CS, Wong RW.
    Arthritis Rheum; 2002 Apr; 46(4):1003-13. PubMed ID: 11953978
    [Abstract] [Full Text] [Related]

  • 10. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [Abstract] [Full Text] [Related]

  • 11. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years.
    Moroni G, Doria A, Mosca M, Alberighi OD, Ferraccioli G, Todesco S, Manno C, Altieri P, Ferrara R, Greco S, Ponticelli C.
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):925-32. PubMed ID: 17699309
    [Abstract] [Full Text] [Related]

  • 12. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial.
    Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, Assmann KJ, Bruijn JA, Weening JJ, van Houwelingen HC, Derksen RH, Berden JH, Dutch Working Party on Systemic Lupus Erythematosus.
    Kidney Int; 2006 Aug; 70(4):732-42. PubMed ID: 16820790
    [Abstract] [Full Text] [Related]

  • 13. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.
    Wang S, Li X, Qu L, Wang R, Chen Y, Li Q, He X, Zhang X, Wang H, Wu J, Xu Y, Chen J.
    Lupus; 2012 Aug; 21(9):1025-35. PubMed ID: 22570338
    [Abstract] [Full Text] [Related]

  • 14. The difference between lupus nephritis class IV-G and IV-S in Koreans: focus on the response to cyclophosphamide induction treatment.
    Kim YG, Kim HW, Cho YM, Oh JS, Nah SS, Lee CK, Yoo B.
    Rheumatology (Oxford); 2008 Mar; 47(3):311-4. PubMed ID: 18204087
    [Abstract] [Full Text] [Related]

  • 15. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis.
    Danieli MG, Palmieri C, Salvi A, Refe MC, Strusi AS, Danieli G.
    J Clin Apher; 2002 Mar; 17(2):72-7. PubMed ID: 12210709
    [Abstract] [Full Text] [Related]

  • 16. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients.
    Ribi C, Cohen P, Pagnoux C, Mahr A, Arène JP, Lauque D, Puéchal X, Letellier P, Delaval P, Cordier JF, Guillevin L, French Vasculitis Study Group.
    Arthritis Rheum; 2008 Feb; 58(2):586-94. PubMed ID: 18240234
    [Abstract] [Full Text] [Related]

  • 17. Pulse cyclophospamide in severe lupus nephritis: Southern Indian experience.
    Das U, Dakshina Murty KV, Prasad N, Prayag A.
    Saudi J Kidney Dis Transpl; 2010 Mar; 21(2):372-8. PubMed ID: 20228536
    [Abstract] [Full Text] [Related]

  • 18. Predictive factors of clinical outcome in patients with diffuse proliferative lupus nephritis treated early by intravenous methylprednisolone pulse therapy.
    Kanno A, Hotta O, Yusa N, Taguma Y.
    Ren Fail; 2007 Mar; 29(1):41-7. PubMed ID: 17365909
    [Abstract] [Full Text] [Related]

  • 19. Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis.
    Demircin G, Oner A, Erdoğan O, Delibaş A, Baysun S, Bülbül M, Bek K, Oksal A.
    Ren Fail; 2008 Mar; 30(6):603-9. PubMed ID: 18661410
    [Abstract] [Full Text] [Related]

  • 20. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study.
    Valeri A, Radhakrishnan J, Estes D, D'Agati V, Kopelman R, Pernis A, Flis R, Pirani C, Appel GB.
    Clin Nephrol; 1994 Aug; 42(2):71-8. PubMed ID: 7955581
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.